14 Investor presentation First six months of 2020 The AM833 phase 2 monotherap with semaglutide trial decreased Weight loss for AM833 plus lifestyle intervention1 % change in body weight 00 -2 Mean baseline: 107.4 kg -4-4 -6 -8-8 -10 - 10.8% -12-12 0 2 4 6 8 10 12 14 16 18 20 22 24 26 0 Weeks 26 AM833 0.3mg Placebo AM833 0.6mg Lira 3.0mg AM833 1.2mg AM833 2.4mg AM833 4.5mg 1 Lifestyle intervention is defined as counselling for a reduced-calorie diet and increased physical activity. Data is based on the trial p 2 Data are observed means, 20 week phase 1b trial dosing increments with semaglutide and AM833 once-weekly with a 16 week do
Download PDF file